Bio-Thera Delivers Positive Phase III Results For Stelara Biosimilar

Hikma Holds Exclusive Rights To Commercialize The Ustekinumab Product In The US

 
• By Chloe Kent

Bio-Thera has announced positive Phase III results for its ustekinumab biosimilar candidate BAT2206, demonstrating that the product is highly similar to originator Stelara in patients with moderate to severe plaque psoriasis. 

Ustekinumab vial
Ustekinumab is used to treat plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis • Source: Shutterstock

More from Biosimilars

More from Products